This compound, however, has shown promise in other conditions including breast cancer migration, inflammatory pain and nausea (Bolognini et al., 2013; Rock, Limebeer, & Parker, 2018; Takeda et al., 2012), with groups suggesting that CBDA is 1,000 times more potent at the 5‐HT1A receptor than CBD (Bolognini et al., 2013). Here, HTR1A is linked to breast carcinoma.